Introduction
AstraZeneca plc (LSE:AZN) markets Calquence (acalabrutinib), an oral Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of certain B-cell blood cancers. In the United Kingdom, Calquence is approved for defined groups of adults with chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL), according to the approved product information. The medicine sits within AstraZeneca’s oncology portfolio and, more specifically, its growing haematology franchise.
This article explains what Calquence is, how acalabrutinib works, which approved indications apply in the UK, and why the product matters commercially to AstraZeneca. It also separates what an MHRA active-substance listing does and does not establish, and it sets out the principal clinical, regulatory and commercial risks that a general investor audience may wish to monitor. Nothing here is medical or financial advice.
What is the medicine?
Calquence is the brand name for acalabrutinib, a small-molecule medicine taken by mouth. It belongs to a class known as BTK inhibitors, which interfere with a signalling protein that certain cancerous B-cells rely on to survive and multiply. According to the UK Summary of Product Characteristics, Calquence is supplied as 100 mg film-coated tablets and is taken twice daily at roughly 12-hour intervals, with or without food.
Acalabrutinib is sometimes described as a second-generation, more selective BTK inhibitor. The intention behind greater selectivity is to reduce certain off-target effects, although individual tolerability varies and prescribing decisions belong to qualified healthcare professionals who weigh the full approved product information.
The medicine was originally introduced as a capsule and later became available as a film-coated tablet, a change intended to simplify administration, including for patients who take acid-reducing medicines. Both the active substance and the medicine are frequently referenced in regulatory documents, which is why acalabrutinib appears in the MHRA index in more than one form, including as acalabrutinib maleate.
Which UK-listed company is connected to it?
Calquence is marketed by AstraZeneca plc, a biopharmaceutical company with a primary listing on the London Stock Exchange under the ticker AZN. The UK marketing-authorisation holder named in the approved product information is AstraZeneca UK Limited, a subsidiary of the group.
The relationship between the product and the listed company is therefore direct: acalabrutinib originated within AstraZeneca’s wider oncology research and development following its acquisition of Acerta Pharma, and AstraZeneca holds the commercial rights. Investors should note that group-level ownership and the specific UK authorisation holder are related but distinct legal facts.
What does the MHRA substance listing establish?
The Medicines and Healthcare products Regulatory Agency (MHRA) publishes an index of products and active substances. An entry for “acalabrutinib” or “acalabrutinib maleate” confirms only that regulatory or product files exist under that active substance.
It does not, by itself, establish current product ownership, commercial rights, revenue, patent status, market exclusivity, clinical superiority, or that every indication has been approved. Crucially, an active-substance listing is not evidence of a new or recent approval. All specific claims in this article about indications and milestones are drawn from the approved product information and company disclosures, not from the substance index alone.
What is the product approved to treat?
According to the UK approved product information, Calquence is indicated for adults with chronic lymphocytic leukaemia (CLL). This includes use in previously untreated CLL, either alone or in combination with other agents such as obinutuzumab or venetoclax as set out in the labelling, and in CLL that has been treated before with at least one prior therapy.
Calquence is also indicated in mantle cell lymphoma (MCL). The approved product information covers use in combination with chemotherapy for certain previously untreated patients, and as a single agent for relapsed or refractory disease within the approved population. Readers should consult the current Summary of Product Characteristics for the precise, up-to-date wording, as indications can change over time.
It is worth stressing that these are defined populations, not blanket approvals. Eligibility can depend on factors such as prior treatment, fitness for particular regimens, and, in some settings, suitability for stem-cell transplant. The label also specifies which combination partners are approved, so descriptions of “first-line CLL” or “relapsed MCL” should always be read against the exact approved wording rather than generalised.
How does the medicine work?
Bruton’s tyrosine kinase (BTK) is an enzyme involved in signalling pathways that help certain B-cells grow and survive. In several B-cell cancers, this signalling becomes part of what keeps malignant cells alive.
Acalabrutinib binds to BTK and blocks its activity, which can interrupt the signals that these cancer cells depend on. This mechanism underpins its use across CLL and MCL. Clinical results have supported approval in the defined populations, but response and tolerability differ between individuals, and the medicine carries warnings and potential adverse effects described in the approved product information.
What are the key clinical and regulatory milestones?
Acalabrutinib first received regulatory approval in the United States in 2017 for mantle cell lymphoma, followed by approvals in chronic lymphocytic leukaemia and by authorisations in the European Union and the United Kingdom in subsequent years. A film-coated tablet formulation was later introduced alongside the original capsule.
More recently, AstraZeneca has reported additional regulatory milestones for Calquence-based regimens. In 2025 the company announced approvals for fixed-duration Calquence-based combinations in first-line CLL in the EU, and combination use in previously untreated MCL in the US, among other developments. Exact indications and dates should be verified against the latest MHRA, EMA, FDA and company sources, as the regulatory picture continues to evolve.
How important is the product to the company’s portfolio?
Calquence is one of AstraZeneca’s established oncology medicines and a central component of its haematology strategy, which historically focused more on solid tumours. AstraZeneca separately discloses Calquence total revenue in its financial results; the company has reported that Calquence revenue exceeded three billion US dollars in 2024, with continued growth reported thereafter.
Where a figure is not separately disclosed for a given period, this article does not estimate it. The broader point is that Calquence is a meaningful contributor to AstraZeneca’s oncology revenue, though it is one of several large products rather than the sole driver of group performance.
AstraZeneca’s oncology business also includes major products in solid tumours, so Calquence should be seen as part of a diversified cancer portfolio. This diversification can cushion the group against a setback in any one product, but it also means Calquence’s individual momentum is only one input into overall oncology growth. AstraZeneca reported group total revenue of roughly 58.7 billion US dollars for the 2025 financial year, of which oncology is a substantial share.
What is the size and nature of the addressable market?
CLL is among the more common adult leukaemias in higher-income countries, and MCL is a rarer, typically more aggressive B-cell lymphoma. Both are chronic or relapsing conditions in many patients, which means treatment can extend over long periods and may involve sequential therapies.
The addressable market is shaped by incidence, diagnosis rates, treatment guidelines, and reimbursement decisions by bodies such as the National Institute for Health and Care Excellence (NICE) in England. Because BTK inhibitors are used across several settings, small shifts in guideline positioning or first-line preference can materially affect the number of eligible patients.
In the UK specifically, access is not automatic on approval. A medicine or regimen must generally be recommended through health-technology appraisal and commissioning processes before it is routinely funded, and confidential commercial arrangements can affect the effective price. This means UK uptake can lag or diverge from approval timing, an important nuance when interpreting the commercial opportunity.
What competing treatments are available?
Calquence competes most directly with other BTK inhibitors, including ibrutinib (a first-generation agent) and zanubrutinib, a newer competitor that has gained significant share in some markets. Industry reporting has noted that zanubrutinib overtook acalabrutinib in certain quarterly sales comparisons, illustrating the intensity of competition.
Beyond BTK inhibitors, other mechanisms compete for the same patients, including the BCL-2 inhibitor venetoclax, often used in fixed-duration combinations, and newer approaches such as non-covalent (reversible) BTK inhibitors like pirtobrutinib. The competitive landscape is therefore dynamic, and clinical choice depends on individual circumstances determined by clinicians.
Competition also plays out in the design of regimens, not only in the choice of molecule. The industry has moved toward fixed-duration, all-oral combinations that allow patients to stop treatment after a defined period, which can influence prescriber and payer preferences. AstraZeneca has pursued Calquence-based combinations partly in response to this shift, but rival regimens are evolving in parallel.
What could support future product growth?
Several factors could support Calquence’s future role, subject to regulatory requirements. These include additional approvals for combination and fixed-duration regimens, longer-term follow-up data, and continued adoption in first-line settings where BTK inhibitors are favoured.
Formulation and convenience improvements, together with real-world evidence on tolerability, may also influence prescribing. However, growth is not guaranteed: it will depend on clinical results, regulatory decisions, pricing, market access and how competing products evolve. Investors may monitor these drivers rather than assume any particular outcome.
What are the principal clinical, regulatory and commercial risks?
Clinically, all medicines carry potential adverse effects and contraindications; BTK inhibitors as a class have recognised safety considerations that clinicians manage on an individual basis, as described in approved labelling. Regulatory risk includes the possibility that new indications are not approved, or that existing indications are varied.
Commercially, the main risks include intensifying competition from other BTK inhibitors and combination regimens, pricing and reimbursement pressure, and eventual loss of exclusivity as patents expire. Currency movements and broader portfolio dynamics at AstraZeneca can also affect how Calquence contributes to reported results.
There is also a degree of trial and evidence risk. Oncology franchises depend on read-outs from ongoing studies that seek to expand or defend a product’s position, and results can be positive, negative or mixed. A disappointing outcome, or a competitor’s stronger data, could weigh on Calquence’s trajectory even where current approvals remain unchanged.
What should investors monitor next?
Investors may wish to monitor future regulatory decisions in the UK, EU and US on new or expanded Calquence indications; head-to-head or comparative clinical data against other BTK inhibitors; and NICE and other reimbursement outcomes that affect UK access.
They may also track disclosed Calquence revenue trends in AstraZeneca’s quarterly and annual results, patent and exclusivity timelines, and the pace at which competitors gain or lose share. Each of these is a factual data point that can be checked against primary sources rather than assumed.
Balanced conclusion
Calquence (acalabrutinib) is a clinically important, directly owned AstraZeneca (LSE:AZN) product with approved uses in defined groups of adults with CLL and MCL, and it is a meaningful part of the group’s oncology revenue. At the same time, it operates in a competitive BTK-inhibitor market where share can shift, and its future value depends on evidence, regulation, pricing and access rather than on any single listing or approval.
For a general investor audience, the reasonable takeaway is that Calquence is a strong asset with clear commercial relevance, but not a guaranteed source of growth. Readers seeking to act on any of this information should consult the primary sources cited and, where relevant, professional advice.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...